Search results for "ACUTE CORONARY SYNDROME"

showing 10 items of 277 documents

Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor?

2004

Abstract Introduction Increased concentrations of homocysteine (tHcy) are considered a potentially modifiable risk factor for coronary heart disease. The relationship between plasma homocysteine and prognosis has been less well studied. The aim of this study was to examine a possible relationship between the homocysteine levels in admission and all cause mortality in subjects presenting with non-ST segment elevation (NSTE) acute coronary syndrome. Methods We studied 854 patients with suspected NSTE acute coronary syndrome admitted consecutively to our institution, tHcy was determined at a median of 3 days from enrolment and was analyzed in tertiles together with classical risk factors and o…

Malemedicine.medical_specialtyAcute coronary syndromeHomocysteineMyocardial InfarctionCoronary Diseasechemistry.chemical_compoundInternal medicinemedicineClinical endpointHumansRisk factorHomocysteineAgedCreatinineAnalysis of Variancebiologybusiness.industryAcute-phase proteinmedicine.diseasePrognosisTroponinSurvival AnalysisSurgerychemistrySpainHeart failureCardiologybiology.proteinLinear ModelsFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Homocysteine and long-term recurrent infarction following an acute coronary syndrome.

2021

En Cardiology Journal. Gdańsk (Polonia) : Via Medica. Vol. 28, n. 4 (01 jul. 2021), pp. 598-606. ISSN 1897-5593. e-ISSN 1898-018X. Este artículo se encuentra disponible en la siguiente URL: https://journals.viamedica.pl/cardiology_journal/article/view/CJ.a2020.0170/52602 En este artículo de investigación también participan: Maria Marco, Teresa García-Ballester, Begoña Zorio, Eduardo Núñez, Francisco J. Chorro, Juan Sanchis y Julio Núñez. Background: There are no well-established predictors of recurrent ischemic coronary events after an acute coronary syndrome (ACS). Higher levels of homocysteine have been reported to be associated with an increased atherosclerotic burden. The primary endpoi…

Malemedicine.medical_specialtyAcute coronary syndromeHomocysteinemedicine.medical_treatmentCoronary heart disease - Risk factors.Infarto de miocardio - Factores de riesgo.Enfermedad coronaria - Factores de riesgo.InfarctionClinical CardiologyRevascularizationCoronary artery diseasechemistry.chemical_compoundInterquartile rangeRisk FactorsInternal medicineMyocardial infarction - Risk factors.medicineHumansMyocardial infarctionAcute Coronary SyndromeHomocysteineAgedacute coronary syndrome coronary artery disease homocysteine recurrent myocardial infarction risk factorsCardiovascular system - Diseases - Risk factors.Framingham Risk Scorebusiness.industryEnfermedades cardiovasculares - Factores de riesgo.General Medicinemedicine.diseaseHospitalizationchemistryCardiologyST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessCardiology journal
researchProduct

Relation of Low Lymphocyte Count to Frailty and its Usefulness as a Prognostic Biomarker in Patients >65 Years of Age With Acute Coronary Syndrome

2020

Low lymphocyte count, as a marker of inflammation and immunosuppression, may be useful for identifying frail patients. In this work, we aimed to evaluate the association between low-relative lymphocyte count (Lymph%) and frailty status in patients >65 years old with acute coronary syndromes (ACS), and whether Lymph% is associated with morbimortality beyond standard prognosticators and frailty. In this prospective observational study, we included 488 hospital survivors of an episode of an ACS >65 years old. Total and differential white blood cells and frailty status were assessed at discharge. Frailty was evaluated using the Fried score at discharge and defined as Fried≥3. The independent as…

Malemedicine.medical_specialtyAcute coronary syndromeMultivariate analysisLymphocytemedicine.medical_treatment030204 cardiovascular system & hematologyLogistic regression03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeInternal medicinemedicineHumansLymphocyte CountProspective Studies030212 general & internal medicineAcute Coronary SyndromeGeriatric AssessmentAgedFrailtyProportional hazards modelbusiness.industryImmunosuppressionPrognosismedicine.diseaseSurvival Ratemedicine.anatomical_structureSpainCardiologyFemaleLymphCardiology and Cardiovascular MedicinebusinessBiomarkersThe American Journal of Cardiology
researchProduct

Influence of Comorbid Conditions on One-Year Outcomes in Non–ST-Segment Elevation Acute Coronary Syndrome

2011

To investigate comorbid conditions with prognostic influence in non-ST-segment elevation acute coronary syndrome (NSTEACS).The study group consisted of a derivation cohort of 1017 patients (admitted from October 1, 2002, through October 1, 2008) and an external validation cohort of 652 patients (admitted from February 1, 2006, through September 30, 2009). Comorbid conditions, including risk factors and components of the Charlson comorbidity index (ChCI) and coronary artery disease-specific index, were recorded. The main outcome was one-year mortality.During follow-up, 103 patients died. After adjusting for variables associated with NSTEACS characteristics (base model), 5 comorbid conditions…

Malemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionComorbidityRisk AssessmentCoronary artery diseaseVentricular Dysfunction LeftInternal medicinemedicineHumansMyocardial infarctionProspective StudiesAcute Coronary SyndromeAgedAged 80 and overbusiness.industryST elevationMortality rateHazard ratioStroke VolumeGeneral MedicineMiddle Agedmedicine.diseasePrognosisComorbiditySurvival AnalysisConfidence intervalSurgeryMultivariate AnalysisCardiologyOriginal ArticleFemalebusiness
researchProduct

Resistin, acute coronary syndrome and prognosis results from the AtheroGene study

2006

Resistin, an adipocyte and macrophage derived cytokine, causes insulin resistance and glucose intolerance. We investigated the impact of resistin as a diagnostic marker in patients with acute coronary syndrome and its prognostic value for future cardiovascular events.Resistin levels were determined in 1153 patients with stable angina (SAP), 380 patients with unstable angina, 278 patients with non-ST-elevation myocardial infarction (NSTEMI) and 111 patients with ST-elevation myocardial infarction (STEMI). All patients have been followed up for a median follow-up of 2.6 years. During follow-up, 70 patients died from cardiovascular causes.Compared to SAP, resistin levels (5.1 ng/mL in SAP) wer…

Malemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionCoronary DiseaseAngina PectorisCoronary artery diseaseImpaired glucose toleranceAnginaElectrocardiographyRisk FactorsInternal medicineHumansMedicineResistinAngina Unstablecardiovascular diseasesMyocardial infarctionRisk factorAgedbusiness.industryUnstable anginaSyndromeMiddle AgedPrognosismedicine.diseaseLipidsSurgeryAcute DiseaseCardiologyFemaleResistinInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersAtherosclerosis
researchProduct

Prognosis and Management of Acute Coronary Syndrome in Spain in 2012: The DIOCLES Study

2015

Abstract Introduction and objectives To identify the current mortality and management of patients admitted for suspected acute coronary syndrome in Spain. The last available registry (2004-2005) reported an in-hospital mortality of 5.7%. Methods The study included patients consecutively admitted between January and June 2012 at 44 hospitals selected at random. Information was collected on clinical course at admission and on events at 6 months. Results A total of 2557 patients admitted with suspected acute coronary syndrome were included: 788 (30.8%) with ST-segment elevation, 1602 (62.7%) without ST-segment elevation, and 167 (6.5%) with unclassified acute coronary syndrome. In-hospital mor…

Malemedicine.medical_specialtyAcute coronary syndromePercutaneousmedicine.medical_treatmentCoronary AngiographyBalloon inflationElectrocardiographyInternal medicinemedicineHumansHospital MortalityRegistriesAcute Coronary SyndromeAgedRetrospective StudiesAged 80 and overManagement of acute coronary syndromebusiness.industryIncidenceClinical courseDisease ManagementPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle AgedPrognosismedicine.diseaseFrequent useHospitalizationCross-Sectional StudiesSpainCardiologyFemalebusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Management of bleeding in patients hospitalized in the intensive cardiac care unit: expert opinion of the Association of Intensive Cardiac Care and S…

2019

ABSTRACT Nowadays, the intensive cardiac care unit (ICCU) provides care for patients with acute coronary syndrome, acute and exacerbated chronic heart failure, cardiogenic shock, sudden cardiac arrest, electrical storm, as well as with indications for urgent cardiac surgical treatment. Most of these patients require the use of 1, 2, or frequently even 3 drugs that act on the blood coagulation pathway. While antithrombotic drugs prevent thromboembolic events, they are associated with a higher risk of bleeding. In this population of patients, bleeding may often have a worse impact on prognosis than the primary disease. In this expert opinion of the Association of Intensive Cardiac Care, we pr…

Malemedicine.medical_specialtyAcute coronary syndromePopulationCardiologyHemorrhagePharmacotherapyFibrinolytic AgentsRisk FactorsThromboembolismAntithromboticmedicineHumansIn patientCardiac Surgical ProceduresIntensive care medicineeducationSocieties MedicalAgedAged 80 and overeducation.field_of_studybusiness.industryCardiogenic shockDisease ManagementSudden cardiac arrestmedicine.diseaseIntensive Care UnitsHeart failureFemalePolandmedicine.symptomCardiology and Cardiovascular MedicinebusinessKardiologia polska
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

2013

Item does not contain fulltext BACKGROUND: Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. METHODS: We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to recei…

Malemedicine.medical_specialtyAcute coronary syndromePrasugrelmedicine.medical_treatmentPremedicationMyocardial InfarctionHemorrhageThiophenesCoronary AngiographyPiperazinesPercutaneous Coronary InterventionDouble-Blind MethodInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassAgedCardiovascular diseases [NCEBP 14]business.industryMedicine (all)Hazard ratioAcute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Coronary Angiography; Premedication; Medicine (all)Percutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedta3121medicine.diseaseConventional PCICardiologyPurinergic P2Y Receptor AntagonistsFemalebusinessPrasugrel HydrochlorideTIMImedicine.drug
researchProduct

Combining Disability and Frailty in an Integrated Scale for Prognostic Assessment After Acute Coronary Syndrome

2018

Malemedicine.medical_specialtyAcute coronary syndromeScale (ratio)Risk AssessmentSeverity of Illness IndexCohort StudiesDisability EvaluationPredictive Value of TestsCause of DeathmedicineHumansHospital MortalityAcute Coronary SyndromeGeriatric AssessmentAgedAged 80 and overFrailtybusiness.industryGeneral MedicinePrognosismedicine.diseaseSurvival AnalysisHospitalizationSpainPhysical therapyFemalebusinessRevista Española de Cardiología (English Edition)
researchProduct